A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the Primary Eradication of H.Pylori.

Trial Profile

A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole), Amoxicillin and Clarithromycin for the Primary Eradication of H.Pylori.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Vonoprazan (Primary) ; Amoxicillin; Clarithromycin; Lansoprazole
  • Indications Helicobacter pylori infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 02 Mar 2016 Results published in the Gut
    • 26 Mar 2015 According to a Takeda and Otsuka media release, Takeda submitted a NDA to the Ministry of Health, Labour and Welfare, Japan for a single pack containing drugs for the eradication of Helicobacter Pylori. One pack contains three drugs, vonoprazan fumarate, amoxicillin and clarithromycin for the first eradication, and other pack contains drugs, vonoprazan fumarate, amoxicillin and metronidazole for the second eradication of Helicobacter pylori.
    • 07 May 2014 According to a Takeda media release, the results of this trial will be presented at the Digestive Disease Week 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top